{"nctId":"NCT00171873","briefTitle":"Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut","startDateStruct":{"date":"2001-09"},"conditions":["Neuroendocrine Tumors"],"count":85,"armGroups":[{"label":"Octreotide LAR (Long Acting Release)","type":"EXPERIMENTAL","interventionNames":["Drug: Octreotide LAR (Long-acting release)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Octreotide LAR (Long-acting release)","otherNames":["SMS995"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Therapy-naive patients with histologically confirmed diagnosis of a locally inoperable or metastasized well-differentiated neuroendocrine tumor of the midgut\n* curative surgery impossible\n* two-dimensional tumor formation assessable by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)\n* Age â‰¥ 18\n* Karnofsky-index \\> 60\n* written informed consent\n* proliferation index for Ki67\n\nExclusion Criteria:\n\n* hypersensitivity to octreotide\n* poorly differentiated or small cell neuroendocrine tumors\n* primary tumor outside of the midgut\n* prior treatment with somatostatin-analogue \\> 4 weeks\n* prior treatment with alpha-interferon, chemotherapy, or chemoembolisation\n* participation in any other clinical trial\n* pregnancy or lactation\n* no secondary malignancy in anamnesis; with the exception of patients without any manifestation of the secondary malignancy (without relapse) after curative therapy within the last five years\n* severe decompensated organ malfunction (heart-, liver- insufficiency)\n\nOther protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)","description":"Median time to tumor progression at the time of the planned interim analysis that includes all data observed until June 2008.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rates According to World Health Organization (WHO) Criteria at 3 Month Intervals","description":null,"classes":[]},{"type":"SECONDARY","title":"Biochemical Response at 3 Month Intervals","description":null,"classes":[]},{"type":"SECONDARY","title":"Symptom Control at 3 Month Intervals","description":null,"classes":[]},{"type":"SECONDARY","title":"Quality of Life (Standardized Questionnaire) at Three-month Intervals in Comparison With the Start of the Study","description":null,"classes":[]},{"type":"SECONDARY","title":"Survival","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":42},"commonTop":["Gastrointestinal disorders","General Health","Hematopoietic system"]}}}